Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-08-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第四次会议相关事项的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent directors' opinion on the company's 2022 half-year fundraising funds storage and usage report. It references compliance with regulatory guidelines on fundraising management and confirms no misuse of funds. The document is a formal opinion related to a specific report but does not contain the full report or detailed financial data itself. It is a regulatory announcement related to fundraising and compliance rather than the fundraising report or a financial report. Given the content and length (757 characters), it fits best as a Regulatory Filing (RNS) rather than a Capital/Financing Update (CAP) or a full report.
2022-08-25 Chinese
第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the Fourth Meeting of the Third Board of Directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and the approval of the 2022 Half-Year Report and a special report on the use of raised funds. The document states that the full 2022 Half-Year Report is disclosed on the Beijing Stock Exchange website, indicating this document is not the report itself but an announcement of the board meeting resolutions. The document length is short (1276 characters), and it primarily serves to announce the board meeting decisions rather than provide substantive financial data or the full report. Therefore, it fits best under Board/Management Information (MANG), as it relates to board meeting resolutions and approvals.
2022-08-25 Chinese
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the lifting of trading restrictions on certain shares. It details the number of shares being unlocked, the shareholders involved, reasons for the unlocking, and the updated shareholding structure. The content focuses on stock unlocking and share trading status rather than financial results, management changes, or regulatory filings. The document length is 2210 characters, which is relatively short and is a specific announcement about share restriction removal. This fits the category of Share Issue/Capital Change (SHA), as it relates to changes in share trading status and capital structure due to lifting of lock-up restrictions.
2022-08-15 Chinese
持股百分之五以上股东减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding the reduction of shareholding by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, shareholding before and after reduction, reduction method, period, price range, and amount. The document is titled as a 'shareholding reduction result announcement' and includes a statement ensuring the accuracy and completeness of the disclosure. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, specifically reporting a change in significant share ownership levels.
2022-07-07 Chinese
持股百分之五以上股东减持股份进展公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the progress of shareholding reduction by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, shareholding percentages before and after reduction, methods and periods of reduction, and risk disclosures related to the share reduction. There is no financial report, earnings data, or management discussion. The document is a notification about changes in major shareholding levels, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication.
2022-05-19 Chinese
关于持股百分之五以上股东减持超过百分之一的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a shareholder holding more than 5% reducing their stake by more than 1%. It includes details about the shareholder, shareholding percentages before and after the change, and related documents. There is no financial report, earnings data, or management discussion. The content matches the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds.
2022-05-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.